190 related articles for article (PubMed ID: 37823872)
1. [Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?].
Rawee P; Eisenga MF
Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823872
[TBL] [Abstract][Full Text] [Related]
2. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
Ogawa C; Tsuchiya K; Maeda K
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769359
[TBL] [Abstract][Full Text] [Related]
4. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S; Tanaka T; Nangaku M
Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
[TBL] [Abstract][Full Text] [Related]
5. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
6. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia inducible factor-prolyl hydroxylase inhibitors in anemic patients with non-dialysis dependent chronic kidney disease: a meta-analysis of randomized clinical trials.
Mohamed MMG; Oyenuga M; Shaikh S; Oyenuga A; Kheiri B; Nwankwo C
Int Urol Nephrol; 2023 Jan; 55(1):167-171. PubMed ID: 35852713
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Therapy for Anemia in Renal Transplantation Patients by Prior Erythropoiesis Stimulating Agent Use.
Nakamura N; Aso S; Nakagawa C; Tachibana M; Fujikawa A; Tsubouchi K; Gunge N; Miyazaki T; Okabe Y; Matsuzaki H; Matsuoka H; Haga N
Transplant Proc; 2023 May; 55(4):829-831. PubMed ID: 37105829
[TBL] [Abstract][Full Text] [Related]
10. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis.
Wu M; Zang C; Ma F; Chen B; Liu J; Xu Z
Clin Exp Nephrol; 2022 Nov; 26(11):1043-1054. PubMed ID: 36006596
[TBL] [Abstract][Full Text] [Related]
12. Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors.
Takahashi A
Nutrients; 2024 Feb; 16(4):. PubMed ID: 38398842
[TBL] [Abstract][Full Text] [Related]
13. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
Locatelli F; Minutolo R; De Nicola L; Del Vecchio L
Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
[TBL] [Abstract][Full Text] [Related]
14. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
Zhao H; Li P; Zhang HL; Jia L
Ren Fail; 2023; 45(2):2258986. PubMed ID: 37724564
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
Packer M
Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
[TBL] [Abstract][Full Text] [Related]
16. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
18. Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study.
Watanabe K; Sato E; Mishima E; Moriya S; Sakabe T; Sato A; Fujiwara M; Fujimaru T; Ito Y; Taki F; Nagahama M; Tanaka K; Kazama JJ; Nakayama M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628932
[TBL] [Abstract][Full Text] [Related]
19. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
20. Anemia in conventional hemodialysis: Finding the optimal treatment balance.
Hasegawa T; Koiwa F; Akizawa T
Semin Dial; 2018 Nov; 31(6):599-606. PubMed ID: 29909605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
